Literature DB >> 18794121

Flt-1 signaling in macrophages promotes glioma growth in vivo.

Mark Kerber1, Yvonne Reiss, Anke Wickersheim, Manfred Jugold, Fabian Kiessling, Matthias Heil, Vadim Tchaikovski, Johannes Waltenberger, Masabumi Shibuya, Karl H Plate, Marcia Regina Machein.   

Abstract

Several lines of evidence indicate that Flt-1, a fms-like tyrosine kinase receptor, which binds to vascular endothelial growth factor (VEGF)-A, VEGF-B, and PlGF, is a positive regulator of angiogenesis in the context of tumor growth and metastasis. However, the molecular basis of its action is still not clear. Besides endothelial cells, Flt-1 is also expressed by other different cell types, including myeloid hematopoeitic cells (monocytes and macrophages). To examine the functions of Flt-1 expressed by bone marrow-derived myeloid cells in supporting tumor growth and angiogenesis, Flt-1 tyrosine kinase-deficient (Flt-1 TK-/-) bone marrow cells were transplanted into lethally irradiated syngeneic recipients. After hematopoietic reconstitution, we orthotopically implanted syngeneic wild-type glioma cells or glioma cells overexpressing either VEGF(164) or PlGF-2. Loss of Flt-1 signaling in bone marrow-derived myeloid cells led to a significant decrease in tumor volume and vascularization in gliomas. VEGF but not PlGF overexpressed by glioma cells restored the tumor growth rate in Flt-1 TK-/- bone marrow chimera. VEGF and PlGF overexpression by tumor cells induced an accumulation of bone marrow-derived myeloid cells into tumor tissue. This infiltration was decreased in tumors grown in Flt-1 TK-/- bone marrow chimeras. When investigating chemokines and growth factors involved in myeloid cell recruitment, we determined elevated SDF-1/CXCL12 levels in VEGF- and PlGF-overexpressing tumors. Collectively, these results suggest that Flt-1 signaling in myeloid cells is essential to amplify the angiogenic response and to promote glioma growth.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18794121     DOI: 10.1158/0008-5472.CAN-07-6241

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  69 in total

1.  Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept.

Authors:  John F de Groot; Yuji Piao; Hai Tran; Mark Gilbert; Hua-Kang Wu; Jun Liu; B Nebiyou Bekele; Tim Cloughesy; Minesh Mehta; H Ian Robins; Andrew Lassman; Lisa DeAngelis; Kevin Camphausen; Alice Chen; W K A Yung; Michael Prados; Patrick Y Wen; John V Heymach
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

Review 2.  Signal transduction by vascular endothelial growth factor receptors.

Authors:  Sina Koch; Lena Claesson-Welsh
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

3.  PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity.

Authors:  Joao Incio; Josh Tam; Nuh N Rahbari; Priya Suboj; Dan T McManus; Shan M Chin; Trupti D Vardam; Ana Batista; Suboj Babykutty; Keehoon Jung; Anna Khachatryan; Tai Hato; Jennifer A Ligibel; Ian E Krop; Stefan B Puchner; Christopher L Schlett; Udo Hoffmman; Marek Ancukiewicz; Masabumi Shibuya; Peter Carmeliet; Raquel Soares; Dan G Duda; Rakesh K Jain; Dai Fukumura
Journal:  Clin Cancer Res       Date:  2016-02-09       Impact factor: 12.531

4.  Simulation-based comparison of two approaches frequently used for dynamic contrast-enhanced MRI.

Authors:  Stefan Zwick; Gunnar Brix; Paul S Tofts; Ralph Strecker; Annette Kopp-Schneider; Hendrik Laue; Wolfhard Semmler; Fabian Kiessling
Journal:  Eur Radiol       Date:  2009-09-01       Impact factor: 5.315

Review 5.  CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?

Authors:  Dan G Duda; Sergey V Kozin; Nathaniel D Kirkpatrick; Lei Xu; Dai Fukumura; Rakesh K Jain
Journal:  Clin Cancer Res       Date:  2011-02-24       Impact factor: 12.531

6.  Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model.

Authors:  Nadja Osterberg; Napoleone Ferrara; Jean Vacher; Simone Gaedicke; Gabriele Niedermann; Astrid Weyerbrock; Soroush Doostkam; Hans-Eckart Schaefer; Karl H Plate; Marcia Regina Machein
Journal:  Neuro Oncol       Date:  2016-03-06       Impact factor: 12.300

Review 7.  PlGF: a multitasking cytokine with disease-restricted activity.

Authors:  Mieke Dewerchin; Peter Carmeliet
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

8.  S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages.

Authors:  Huaqing Wang; Leying Zhang; Ian Y Zhang; Xuebo Chen; Anna Da Fonseca; Shihua Wu; Hui Ren; Sam Badie; Sam Sadeghi; Mao Ouyang; Charles D Warden; Behnam Badie
Journal:  Clin Cancer Res       Date:  2013-05-29       Impact factor: 12.531

9.  Vascular Endothelial Growth Factor Receptor 1 morpholino increases graft survival in a murine penetrating keratoplasty model.

Authors:  Yang Kyung Cho; Xiaohui Zhang; Hironori Uehara; Jason R Young; Bonnie Archer; Balamurali Ambati
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-12-19       Impact factor: 4.799

10.  M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis.

Authors:  Yoshiaki Kubota; Keiyo Takubo; Takatsune Shimizu; Hiroaki Ohno; Kazuo Kishi; Masabumi Shibuya; Hideyuki Saya; Toshio Suda
Journal:  J Exp Med       Date:  2009-04-27       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.